Clavis Pharma announces negative outcome of pivotal LEAP Trial with CP-4126 in Patients with Metastatic Pancreatic Cancer

19-Nov-2012 - Clavis Pharma ASA announced results of the LEAP (Low hENT1 and Adenocarcinoma of the Pancreas) study of CP-4126 (also known as CO-101), versus gemcitabine in metastatic pancreatic cancer. The trial, which was conducted by partner Clovis Oncology, Inc., showed that there was no difference in ...

Clavis Pharma's CP-4126 Enters New Phase II Clinical Trial in Pancreatic Cancer Patients Refractory to 1st line Gemcitabine Therapy

07-Feb-2011 - Clavis Pharma announced that its partner, Clovis Oncology, Inc., has recruited the first patient into a Phase II clinical study (CO-101-003 study) with CP-4126 (also known as CO-101). This trial will investigate the use of CP-4126 as a 2nd line treatment for advanced, metastatic pancreatic cancer ...

Clavis Pharma and Clovis Oncology Extend Partnership and Sign New $205 Million Deal for Development and Commercialisation

12-Nov-2010 - Clavis Pharma ASA and Clovis Oncology, Inc., announced a new agreement for the further development and commercialisation of CP-4126 (also known as CO-101), which is currently in Phase II development in pancreatic cancer. CP-4126 is a novel, patented, lipid-conjugated form of the anti-cancer drug ...

Clavis Pharma Announces Recruitment of Patients in Phase II Study comparing CP-4126 with gemcitabine in pancreatic cancer

10-Aug-2010 - Clavis Pharma and its partner Clovis Oncology, Inc. announce that the first two patients have been recruited into a Phase II clinical study comparing CP-4126 (also known as CO-1.01) with gemcitabine in the treatment of patients with pancreatic cancer. The trial is being conducted by Clovis ...

Clavis Pharma announces the appointment of Athos Gianella-Borradori, MD

25-Jun-2010 - Clavis Pharma ASA announces the appointment of Athos Gianella-Borradori MD as Chief Medical Officer (CMO). Dr Gianella-Borradori is an experienced onco-hematologist and drug developer, with 30 years experience in the field. He spent the past 20 years in industry, focused on translational ...

Clavis Pharma Licenses Rights to hENT1 antibody to Ventana Medical Systems, Inc.

04-May-2010 - Clavis Pharma ASA announced that it has entered into a licence agreement with Ventana Medical Systems, Inc. providing Ventana with exclusive access to Clavis Pharma’s monoclonal antibody targeting human nucleoside transporter 1 (hENT1) and to the hybridoma cell line that produces the antibody. ...

Clovis Oncology has signed an agreement to Develop and Commercialize hENT1 Companion Diagnostic with Ventana Medical Systems

26-Apr-2010 - Clavis Pharma ASA noted that Clovis Oncology, it’s partner in the development and commercialisation of Clavis Pharma drug candidate CP-4126, and Ventana Medical Systems, Inc. have entered into a collaboration agreement to develop a companion diagnostic to CP-4126 (also known as CO-101) for ...

Clavis Pharma receives US Orphan Drug Designation for CP-4126 to treat pancreatic cancer

12-Jan-2010 - Clavis Pharma announced that the US Food & Drug Administration (FDA) has granted orphan drug designation to CP-4126 for the treatment of pancreatic cancer. The designation follows the equivalent designation given by the European Commission in October last year. “There is an urgent need for new ...

Clavis Pharma and Clovis Oncology Sign Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126

Clavis Pharma to receive up to $380 million in staged payments, including a $15 million signing fee, and tiered double-digit royalties on sales

25-Nov-2009 - Clavis Pharma ASA and Clovis Oncology, Inc. announced an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer. CP-4126 is a patented, lipid-conjugated form of the anti-cancer drug ...

The European Commission grants Orphan Drug Designation for Intravenous CP-4126 for the Treatment of Pancreatic Cancer

03-Nov-2009 - Clavis Pharma ASA announced that the European Commission has granted Orphan Drug Designation (Orphan Medicinal Product) for Intravenous CP-4126 for the treatment of pancreatic cancer. The designation follows the recommendation given by the European Medicines Agency (EMEA) in September this ...